Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice.

van Oosterwijk JG, Li C, Yang X, Opferman JT, Sherr CJ.

Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7420-7425. doi: 10.1073/pnas.1707292114. Epub 2017 Jun 26.

2.

Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.

Vo BT, Li C, Morgan MA, Theurillat I, Finkelstein D, Wright S, Hyle J, Smith SMC, Fan Y, Wang YD, Wu G, Orr BA, Northcott PA, Shilatifard A, Sherr CJ, Roussel MF.

Cell Rep. 2017 Mar 21;18(12):2907-2917. doi: 10.1016/j.celrep.2017.02.073.

3.

A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.

Sherr CJ.

N Engl J Med. 2016 Nov 17;375(20):1920-1923. No abstract available.

PMID:
27959598
4.

Targeting CDK4 and CDK6: From Discovery to Therapy.

Sherr CJ, Beach D, Shapiro GI.

Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11. Review.

5.

Forging a signature of in vivo senescence.

Sharpless NE, Sherr CJ.

Nat Rev Cancer. 2015 Jul;15(7):397-408. doi: 10.1038/nrc3960. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

PMID:
26105537
6.

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.

Blood. 2015 Feb 26;125(9):1444-51. doi: 10.1182/blood-2014-09-601062. Epub 2014 Dec 12.

7.

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW.

Genes Dev. 2014 Aug 15;28(16):1800-14. doi: 10.1101/gad.244368.114.

8.

Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model.

Ramsey LB, Janke LJ, Edick MJ, Cheng C, Williams RT, Sherr CJ, Evans WE, Relling MV.

Pharmacogenet Genomics. 2014 May;24(5):263-71. doi: 10.1097/FPC.0000000000000044.

9.

Simultaneous gene editing by injection of mRNAs encoding transcription activator-like effector nucleases into mouse zygotes.

Li C, Qi R, Singleterry R, Hyle J, Balch A, Li X, Sublett J, Berns H, Valentine M, Valentine V, Sherr CJ.

Mol Cell Biol. 2014 May;34(9):1649-58. doi: 10.1128/MCB.00023-14. Epub 2014 Feb 24.

10.

Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells.

Li C, Finkelstein D, Sherr CJ.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1112-21. doi: 10.1073/pnas.1302184110. Epub 2013 Mar 4.

11.

Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.

Volanakis EJ, Boothby MR, Sherr CJ.

Exp Hematol. 2013 Apr;41(4):377-86. doi: 10.1016/j.exphem.2012.11.006. Epub 2012 Nov 23.

12.

How politics trumped peer review at Texas cancer institute.

Sherr CJ.

BMJ. 2012 Nov 15;345:e7334. doi: 10.1136/bmj.e7334. No abstract available.

PMID:
23153837
13.

Ink4-Arf locus in cancer and aging.

Sherr CJ.

Wiley Interdiscip Rev Dev Biol. 2012 Sep-Oct;1(5):731-41.

14.

Expression of arf tumor suppressor in spermatogonia facilitates meiotic progression in male germ cells.

Churchman ML, Roig I, Jasin M, Keeney S, Sherr CJ.

PLoS Genet. 2011 Jul;7(7):e1002157. doi: 10.1371/journal.pgen.1002157. Epub 2011 Jul 21.

15.

Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.

Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, Sorrentino BP.

Blood. 2011 May 19;117(20):5453-62. doi: 10.1182/blood-2010-09-309831. Epub 2011 Mar 22.

16.

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT.

Blood. 2011 Mar 31;117(13):3585-95. doi: 10.1182/blood-2010-08-301267. Epub 2011 Jan 24.

17.

Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells.

Ayrault O, Zhao H, Zindy F, Qu C, Sherr CJ, Roussel MF.

Cancer Res. 2010 Jul 1;70(13):5618-27. doi: 10.1158/0008-5472.CAN-09-3740. Epub 2010 Jun 1.

18.

Developmental strategies for evasion of Arf tumor suppression.

Volanakis EJ, Sherr CJ.

Cell Cycle. 2010 Jan 1;9(1):14-5. Epub 2010 Jan 21. No abstract available.

PMID:
20009580
19.

Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.

Volanakis EJ, Williams RT, Sherr CJ.

Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.

20.

Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf.

Su X, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, Flores ER.

EMBO J. 2009 Jul 8;28(13):1904-15. doi: 10.1038/emboj.2009.151. Epub 2009 Jun 4.

21.

Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice.

Gromley A, Churchman ML, Zindy F, Sherr CJ.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6285-90. doi: 10.1073/pnas.0902310106. Epub 2009 Apr 1. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9120.

22.

Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma.

Ayrault O, Zindy F, Rehg J, Sherr CJ, Roussel MF.

Mol Cancer Res. 2009 Jan;7(1):33-40. doi: 10.1158/1541-7786.MCR-08-0369.

23.

Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.

Forget A, Ayrault O, den Besten W, Kuo ML, Sherr CJ, Roussel MF.

Cell Cycle. 2008 Dec;7(23):3737-46. Epub 2008 Dec 13.

24.

The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.

Williams RT, Sherr CJ.

Cold Spring Harb Symp Quant Biol. 2008;73:461-7. doi: 10.1101/sqb.2008.73.039. Epub 2008 Nov 21. Review.

PMID:
19028987
25.

Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3.

Kuo ML, den Besten W, Thomas MC, Sherr CJ.

Cell Cycle. 2008 Nov 1;7(21):3378-87. Epub 2008 Nov 4.

PMID:
18948745
26.

BCR-ABL and CDKN2A: a dropped connection.

Williams RT, Sherr CJ.

Nat Rev Cancer. 2008 Jul;8(7):563; author reply 563. doi: 10.1038/nrc2368-c1. No abstract available.

PMID:
18574466
27.

Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.

Mullighan CG, Williams RT, Downing JR, Sherr CJ.

Genes Dev. 2008 Jun 1;22(11):1411-5. doi: 10.1101/gad.1673908.

28.

Hzf regulates adipogenesis through translational control of C/EBPalpha.

Kawagishi H, Wakoh T, Uno H, Maruyama M, Moriya A, Morikawa S, Okano H, Sherr CJ, Takagi M, Sugimoto M.

EMBO J. 2008 May 21;27(10):1481-90. doi: 10.1038/emboj.2008.76. Epub 2008 Apr 17.

29.

Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Williams RT, den Besten W, Sherr CJ.

Genes Dev. 2007 Sep 15;21(18):2283-7. Epub 2007 Aug 30.

30.
31.

Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors.

Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF.

Cancer Res. 2007 Mar 15;67(6):2676-84.

32.
33.

Divorcing ARF and p53: an unsettled case.

Sherr CJ.

Nat Rev Cancer. 2006 Sep;6(9):663-73. Epub 2006 Aug 17. Review.

PMID:
16915296
34.

p53-Dependent and -independent functions of the Arf tumor suppressor.

Sherr CJ, Bertwistle D, DEN Besten W, Kuo ML, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF.

Cold Spring Harb Symp Quant Biol. 2005;70:129-37. Review.

PMID:
16869746
35.

N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development.

Zindy F, Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11579-83. Epub 2006 Jul 24.

36.

Autophagy by ARF: a short story.

Sherr CJ.

Mol Cell. 2006 May 19;22(4):436-7. Review.

37.

Ubiquitination of, and sumoylation by, the Arf tumor suppressor.

den Besten W, Kuo ML, Tago K, Williams RT, Sherr CJ.

Isr Med Assoc J. 2006 Apr;8(4):249-51.

38.

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Williams RT, Roussel MF, Sherr CJ.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93. Epub 2006 Apr 17.

39.

The CDK inhibitor p18Ink4c is a tumor suppressor in medulloblastoma.

Uziel T, Zindy F, Sherr CJ, Roussel MF.

Cell Cycle. 2006 Feb;5(4):363-5. Epub 2006 Feb 15.

PMID:
16479172
40.
41.

The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation.

Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, Rehg JE, Calabrese C, Solecki D, Eberhart CG, Sherr SE, Plimmer S, Clifford SC, Hatten ME, McKinnon PJ, Gilbertson RJ, Curran T, Sherr CJ, Roussel MF.

Genes Dev. 2005 Nov 15;19(22):2656-67. Epub 2005 Oct 31.

42.

Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway.

Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE.

Dev Dyn. 2005 Dec;234(4):922-33.

43.

Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.

den Besten W, Kuo ML, Williams RT, Sherr CJ.

Cell Cycle. 2005 Nov;4(11):1593-8. Epub 2005 Nov 14.

PMID:
16205118
44.

Sumoylation induced by the Arf tumor suppressor: a p53-independent function.

Tago K, Chiocca S, Sherr CJ.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7689-94. Epub 2005 May 16.

45.

Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.

Bertwistle D, Zindy F, Sherr CJ, Roussel MF.

Hybrid Hybridomics. 2004 Oct;23(5):293-300.

PMID:
15672607
46.

Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor.

Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K.

Mol Cell Biol. 2005 Jan;25(1):220-32.

47.

Living with or without cyclins and cyclin-dependent kinases.

Sherr CJ, Roberts JM.

Genes Dev. 2004 Nov 15;18(22):2699-711. Review.

48.

Antagonism of Myc functions by Arf.

Cleveland JL, Sherr CJ.

Cancer Cell. 2004 Oct;6(4):309-11.

49.

N-Terminal polyubiquitination of the ARF tumor suppressor, a natural lysine-less protein.

Kuo ML, den Besten W, Sherr CJ.

Cell Cycle. 2004 Nov;3(11):1367-9. Epub 2004 Nov 15.

PMID:
15467472
50.

N-terminal polyubiquitination and degradation of the Arf tumor suppressor.

Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ.

Genes Dev. 2004 Aug 1;18(15):1862-74.

Supplemental Content

Support Center